BioSpace News Archive

Spring 2020 Release Delivers New Integrations, an Updated UI and Standards Compliance Features to Optimize Efficiency and Capture More Revenue

Patent protects foundational intellectual property and pioneering work on Pandion’s therapeutic autoimmune regulatory protein (TALON) drug design platform CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Pandion Therapeutics , a clinical-stage, privately held biotechnology company developing modular protein therapeutics for autoimmune diseases, announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,676,516 with claims covering b

New location provides pharmacy services and home delivery to its growing base of hospice patients in the Bay Area and Western US.

NSF Funds Neocortex , a Groundbreaking AI Supercomputer, at PSC The National Science Foundation awarded $5 million to the Pittsburgh Supercomputing Center to build Neocortex, an AI supercomputer that will introduce revolutionary technologies

After encouraging preliminary results in the treatment of critically-ill COVID-19 patients at a military hospital in the United States and fourteen other hospitals in Europe, the Department of Defense has selected the Seraph®100 Microbind® Affinity Blood Filter (Seraph 100) as one of its main interventions in a pivotal, US-based randomized controlled trial. Financial support for the multi-center trial will be provided

Bio-engineered analog of CBD (CBDVHS) exhibited highly significant potency when compared to CBD in lowering biomarkers associated with inflammation and fibrosis in a validated human tissue model of ocular disease Contrary to historical studies of CBD, CBDVHS was not associated with an elevation in intraocular pressure Long Beach, Calif., June 09, 2020 (GLOBE NEWSWIRE) -- -- Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address g

FDA-cleared iHEARtest™ now available free of charge to mitigate impact of COVID-19 pandemic

CytoSorbents Corporation (NASDAQ:CTSO), a critical care immunotherapy leader specializing in blood purification, announced today that it was awarded a Defense Health Agency Small Business Technology Transfer (STTR) Phase III contract, valued at up to $2,897,172 over 2 years, to advance its HemoDefend-BGA plasma and whole b

— Restructured HealthCare Royalty Partners elobixibat royalty monetization agreement nets additional $15M in non-dilutive capital — — Initial draw down of $10M on debt facility of up to $80M with Hercules Capital —

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that it is expected to join the Russell 2000 ® Index at the conclusion of the annual Russell US Indexes reconstitution after the close of equity markets on June 26, 2020 .